<DOC>
	<DOCNO>NCT02691728</DOCNO>
	<brief_summary>This study evaluate safety efficacy 12 week treatment LDV/SOF FDC patient Chronic GT1 GT4 HCV infection autoimmune disease</brief_summary>
	<brief_title>Study Investigate Efficacy Safety Ledipasvir/Sofosbuvir Fixed-Dose Combination 12 Weeks Subjects With Chronic Genotype 1 4 HCV Infection With Autoimmune Disease</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Chronic GT1 GT4 HCV Infection Diagnosed autoimmune disease ( rheumatoid arthritis , psoriatic arthritis , lupus , etc . ) currently receive treatment condition . Infection HIV HBV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>